Welcome to the MedTek21 News Center

September 6, 2017

MedTek21 to Exhibit at the SoftWriters 9th Annual FrameworkLTC Users Conference

MedTek21, a leading provider of personalized medication management software, will be exhibiting as a sponsor at the 9th Annual SoftWriters FrameworkLTC Users Conference.  Attendees will be able to demo new functionality and learn more about MedTek21’s seamless integration with FrameworkLTC. The […]
February 21, 2017

Integrity Pharmacy chooses MedTek21

Integrity Pharmacy chooses MedTek21 to Power Innovative Personalized Medication Management Program for Home Health and Home Care Patients Enhances Integrity’s leading full-service pharmacy program for home health and home care with benefits to patient safety, outcomes and quality of life […]
January 19, 2017
pro-genex_logo_lgpng copy

Pro-GeneX and MedTek21 Launch Innovative Program for Long-Term Care Providers

Read the full release here ATLANTA,GA and WEST CHESTER, PA Jan. 19, 2017 Pro-GeneX, LLC powered by MedTek21 today announced an innovative program for long-term care providers to manage medication risk for their patient populations. The Pro-GeneX service, powered by […]
December 15, 2016

MedTek21 Partners with Translational Software

MedTek21 and Translational Software (TSI) announced the TSIs PGx knowledge platform and Application Programming Interface (API) will enable PGx-based prescribing seamlessly within MedTek21’s population health and medication risk management platform. This partnership will help to guide treatment decisions and support […]
December 10, 2016

JAMA: Getting Pharmacogenomics Into the Clinic

What if there were a way to know if a depressed patient would respond to an antidepressant—before it was prescribed? Or to predict a bleeding event from an antiplatelet therapy? In recent years, advances in genetic testing have made such […]
November 29, 2016

Personalized Management of Chronic Pain

A powerful case study in how personalized medication management program can help significantly improve patient quality. Given that the patient was a CYP2C9 intermediate metabolizer, he had approximately one-half the normal enzyme activity; he would require less than standard dosages […]